Factor VIII glycoforms

1. A method of producing an isolated glycosylated protein having factor VIII procoagulant activity comprising the amino acid sequence of SEQ ID NO: 1, the method comprising:

obtaining cells comprising a heterologous nucleic acid encoding the protein;

culturing the cells under plasma derived protein-free conditions to produce the protein, and

isolating the protein thereby produced,

wherein the protein comprises an N-linked oligosaccharide having an alpha-(2,6)-linked sialic acid.

2. The method of claim 1 , wherein the cells are obtained from human embryonic kidney cells.

3. The method of claim 1 , wherein the cells are obtained from human embryonic kidney 293 cells.

4. The method of claim 1 , further comprising the step of formulating the protein into a pharmaceutical preparation.

5. A method of producing an isolated glycosylated protein having factor VIII procoagulant activity comprising the amino acid sequence of SEQ ID NO: 1, the method comprising:

obtaining cells comprising a heterologous nucleic acid encoding the protein;

culturing the cells under plasma derived protein-free conditions to produce the protein, and

isolating the protein thereby produced,

wherein the protein comprises an N-linked oligosaccharide comprising a bisecting GlcNAc linked to a core beta-mannose.

6. The method of claim 5 , wherein the cells are obtained from human embryonic kidney cells.

7. The method of claim 5 , wherein the cells are obtained from human embryonic kidney 293 cells.

8. The method of claim 5 , further comprising the step of formulating the protein into a pharmaceutical preparation.

9. A method of producing an isolated glycosylated protein having factor VIII procoagulant activity comprising the amino acid sequence of SEQ ID NO: 1, the method comprising:

culturing cells comprising a heterologous nucleic acid encoding the protein in plasma derived protein-free medium to express the protein, and

isolating the protein thereby produced,

wherein the protein is expressed at a level of about 2 μU/c/d or greater.

10. The method of claim 9 , further comprising the step of formulating the protein into a pharmaceutical preparation.

11. The method of claim 9 , wherein the protein is expressed at a level of about 4 μU/c/d or greater.

12. The method of claim 11 , further comprising the step of formulating the protein into a pharmaceutical preparation.

13. The method of claim 9 , wherein the protein is expressed at a level of about 5 μU/c/d or greater.

14. The method of claim 13 , further comprising the step of formulating the protein into a pharmaceutical preparation.

15. The method of claim 9 , wherein the protein is expressed at a level of about 15 μU/c/d or greater.

16. The method of claim 15 , further comprising the step of formulating the protein into a pharmaceutical preparation.

17. The method of claim 9 , wherein the protein comprises an N-linked oligosaccharide having an alpha-(2,6)-linked sialic acid.

18. The method of claim 10 , wherein the protein comprises an N-linked oligosaccharide having an alpha-(2,6)-linked sialic acid.

19. The method of claim 11 , wherein the protein comprises an N-linked oligosaccharide having an alpha-(2,6)-linked sialic acid.

20. The method of claim 12 , wherein the protein comprises an N-linked oligosaccharide having an alpha-(2,6)-linked sialic acid.

21. The method of claim 13 , wherein the protein comprises an N-linked oligosaccharide having an alpha-(2,6)-linked sialic acid.

22. The method of claim 14 , wherein the protein comprises an N-linked oligosaccharide having an alpha-(2,6)-linked sialic acid.

23. The method of claim 15 , wherein the protein comprises an N-linked oligosaccharide having an alpha-(2,6)-linked sialic acid.

24. The method of claim 16 , wherein the protein comprises an N-linked oligosaccharide having an alpha-(2,6)-linked sialic acid.

25. The method of claim 9 , wherein the protein comprises an N-linked oligosaccharide comprising a bisecting GlcNAc linked to a core beta-mannose.

26. The method of claim 10 , wherein the protein comprises an N-linked oligosaccharide comprising a bisecting GlcNAc linked to a core beta-mannose.

27. The method of claim 11 , wherein the protein comprises an N-linked oligosaccharide comprising a bisecting GlcNAc linked to a core beta-mannose.

28. The method of claim 12 , wherein the protein comprises an N-linked oligosaccharide comprising a bisecting GlcNAc linked to a core beta-mannose.

29. The method of claim 13 , wherein the protein comprises an N-linked oligosaccharide comprising a bisecting GlcNAc linked to a core beta-mannose.

30. The method of claim 15 , wherein the protein comprises an N-linked oligosaccharide comprising a bisecting GlcNAc linked to a core beta-mannose.

31. The method of claim 9 , wherein the cells are obtained from human embryonic kidney cells.

32. The method of claim 9 , wherein the cells are obtained from human embryonic kidney 293 cells.

33. A method of producing an isolated glycosylated protein having factor VIII procoagulant activity comprising the amino acid sequence of SEQ ID NO: 1, the method comprising:

culturing cells comprising a heterologous nucleic acid encoding the protein in serum free medium supplemented with human plasma proteins to express the protein, and

isolating the protein thereby produced,

wherein the protein is expressed at a level of about 10 μU/c/d or greater.

34. The method of claim 33 , wherein the protein is expressed at a level of about 15 μU/c/d or greater.

35. The method of claim 33 , wherein the protein is expressed at a level of about 20 μU/c/d or greater.

36. The method of claim 33 , wherein the protein comprises an N-linked oligosaccharide having an alpha-(2,6)-linked sialic acid.

37. The method of claim 33 , wherein the protein comprises an N-linked oligosaccharide comprising a bisecting GlcNAc linked to a core beta-mannose.

38. The method of claim 33 , further comprising the step of formulating the protein into a pharmaceutical preparation.